Previous 10 | Next 10 |
Stoke Therapeutics (STOK -2.1%) disclosed interim data from its Phase 1/2a MONARCH study for Antisense Oligonucleotide, STK-001 in children and adolescents with Dravet Syndrome, a hereditary form of epilepsy leading to seizures. In the trial involving subjects aged 2 to 18 years, STK-001 was ...
– Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug – – 70.6% (12/17) of patients treated with STK-001 experienced a reduction from baseline in convulsive seizure frequency measu...
The following slide deck was published by Stoke Therapeutics, Inc. in conjunction with this event. For further details see: Stoke Therapeutics (STOK) Investor Presentation -Slideshow
New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Stoke Therapeutics, Inc. (NASDAQ: STOK) breached their fiduciary duties to shareholders. The investigation conc...
J.P. Morgan has upgraded shares of Stoke Therapeutics (STOK +14.5%) to overweight from neutral with a $41 price target (~47% return) Analyst Jessica Fye says Stoke has upcoming potentially derisking events such as additional phase 1/2a data of STK-101 in Dravet syndrome expected early next mo...
Gainers: iSpecimen (NASDAQ:ISPC) +120%, MultiPlan (NYSE:MPLN) +21%, Provention Bio PRVB +20%, Stoke Therapeutics (NASDAQ:STOK) +16%, Star Equity STRR +14%. Losers: Gracell Biotechnologies (NASDAQ:GRCL) -31%, Aurinia Pharmaceuticals (NASDA...
– Data from the positive interim analysis of the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome will be presented – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying...
Gainers: Voyager (NASDAQ:VYGR) +44%. Grom Social Enterprises (NASDAQ:GROM) +26%. Bit Digital (NASDAQ:BTBT) +16%. Resonant (NASDAQ:RESN) +16%. Affirm Holdings (NASDAQ:AFRM) +14%. Acer (NASDAQ:ACER) +12%. Acuity Brands (NYSE:AYI) +12%. SGOCO Group (NASDAQ:SGOC) +14%. Xenon Pharmaceuticals (NASD...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Can...
– Results show that single doses of STK-001 up to 30mg and multiple doses of 20mg were well-tolerated with no safety concerns related to the study drug – – A trend toward a reduction in convulsive seizure frequency was observed among patients treated with ...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...